Clinical Trial Update: A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sequential use of Tarceva (erlotinib) with Gemcitabine as first-line therapy for advanced non-small cell lung cancer has been termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-04-02